Postconsolidation immunotherapy in leukaemia remission

摘要

320 patients with AML were classified as being in first complete remission (CR1) or in subsequent complete remission (CR>1), and were randomly assigned to ten 21-day treatment cycles of HDC and interleukin 2, or to control. 3 years after enrolment, CR1 patients assigned HDC and interleukin 2 had higher leukaemia-free survival than did controls (40% vs 26%). No significant difference was found between the two CR>1 groups. "Overall survival was not significantly affected by treatment", says Brune, "but the study was not powered to detect that".